Vaccines moving beyond the next frontier

Vaccines are considered as one the most efficient approach to fight life threatening infectious diseases for a while. Nevertheless there is still unmet medical needs to be addressed. Former and currently in use approaches and technologies had reach their limit. We clearly have to design other ways to cross the current frontier. New technologies should be a key enabler to be created in association with new “business” and operating model. We will broaden the field of application opportunity within the anti infectious areas giving access to more population. Others therapeutic territories should be explore using the immune systems as beyond the historic ways. Let’s explore this new potential space for the benefit of the patient.

Biography

Rene Labatut has experience in CMC Management in Biopharmaceutical Industry from research and development to manufacturing in highly regulated environment (US, EU, Japan, China etc). He has developed a worldwide international skill set in innovation, technology transfer, licensing in and out and acquisition integration management. He is the Vice President of Manufacturing Technology of Sanofi Pasteur, the vaccines division of Sanofi. He has delivered numerous speeches in reputed conferences and has been serving as a steering Committee Member of Center for Biomedical Innovation at MIT. He has brought significant contribution to several key healthcare product developments like ceredase, thymoglobulin, hexavalent pediatric, flu and dengue vaccines. He holds PhD in Biochemistry, Master in Bioengineering from National Institute of Applied Sciences, Master in Molecular Biology from Lyon I University and Master in Business from Lyon III University.

Rene.Labatut@sanofipasteur.com